This report also provides a detailed analysis of the current mucopolysaccharidosis marketed drugs and late-stage pipeline ...

Jobsite Fan Market projected to reach USD 1.43 billion by 2035, driven by demand for workplace safety, energy efficiency, and smart ventilation solutions. ROCKVILLE, MD , MD, UNITED STATES, July 15, ...

The FDA cited manufacturing issues but did not flag problems with Ultragenyx’s data package for UX111, with the biotech ...

During the two decades that lapsed since “ironome” was coined for the ensemble of proteins associated with iron metabolism, a surge of iron-driven biological processes have been recognized as ...

Following our analysis of the options activities associated with Ultragenyx Pharmaceutical, we pivot to a closer look at the company's own performance. With a volume of 9,702,498, the price of RARE is ...

Orchard Therapeutics, a Kyowa Kirin company, today announced the last patient has been treated in a registrational trial ...

Mucopolysaccharidosis type IIIB, or Sanfilippo syndrome type B, is an autosomal recessive disease caused by pathogenic mutations in the NAGLU gene, encoding a lysosomal enzyme involved in the ...

Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by European Commission (EC) ...

Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex ...

Explore the competitive landscape of Mucopolysaccharidosis I (Hurler syndrome) Therapeutics. In 2024, over 1,740 cases were diagnosed across 16 count ...

Explore the competitive landscape of Mucopolysaccharidosis I (Hurler syndrome) Therapeutics. In 2024, over 1,740 cases were diagnosed across 16 countries. With one FDA-approved drug, the pipeline ...

DelveInsight’s, “Mucopolysaccharidosis Type I Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Mucopolysaccharidosis Type I pipeline ...